Science Pool

Unravelling the Mechanism of TAK875 DILI

TAK-875 (fasiglifam) is a GPR40 agonist which was developed for the treatment of type 2 diabetes. However, TAK-875 was withdrawn from phase III clinical trials due to drug-induced liver injury (DILI).

In this poster, we focus on:

  • investigating the mechanism behind the hepatotoxicity of TAK-875
  • an in-depth understanding of the effect of TAK-875 on mitochondrial toxicity 
  • understanding the impact of plasma protein binding

Read our poster to learn more about our research!

Sounds interesting?
Enter your details below to continue reading…

By clicking on ‘Continue’ I agree that my data is being transferred to the Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our Privacy Policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Join our community

Discover the exclusive benefits on offer if you join our community.